Stemcentrx was a biotechnology company focused on developing cancer therapeutics by targeting cancer stem cells, which are believed to drive tumor growth and resistance to traditional treatments. Founded in 2008 by Brian Slingerland and Scott Dylla, the company was based in South San Francisco and pursued a novel approach to oncology drug development.
The company attracted significant attention from investors, raising substantial venture funding before being acquired by AbbVie in 2016 for approximately $5.8 billion, making it one of the largest biotech acquisitions at the time. However, Stemcentrx's lead drug candidate, Rova-T, ultimately failed in clinical trials, and AbbVie discontinued the program in 2019, representing a significant setback for the cancer stem cell approach to drug development.
Stemcentrx has received investment from 1 venture capital firm.
Biotech company that developed cancer therapeutics targeting cancer stem cells before being acquired by AbbVie.
Stemcentrx has received investment from Versant Ventures. These venture capital firms and investors provide both capital and strategic support.
Stemcentrx operates in the Biotech sector. Biotech company that developed cancer therapeutics targeting cancer stem cells before being acquired by AbbVie.
